4] cells) were stained with monoclonal antibodies against toll-like receptor (TLR)-4, HLA-DR (eBioscience, Vienna, Austria), CD14, CD80, CD86, CD40 (Bio-Rad AbD Serotec, Puchheim, Germany) for DCs and against CD4, CD69, CTLA-4, CD40L (eBioscience) and CD54
(Bio-Rad AbD Serotec) for allogeneic [CD4.
The Effect of intensive moderate and downhill running on human blood lymphocytes expressing the adhesion activation molecules CD54
(Icam -1), CD18, and CD53.
Defects in adhesion molecules CD29 (beta 1 integrin), which is essential for leukocyte extravasation, and CD54
(ICAM-1), which is involved in transvascular lymphocyte migration, have been suggested as an explanation for the intravascular localization (8); however, the mechanism is likely multifactorial and more studies are needed.
RT-PCR primers for pluripotency (Oct3/4, Nanog, Sox2), MSC surface markers (CD4, CD8A, CD25, CD33, CD34, CD44, CD54
, CD61, CD80, CD105, CD117, Flk-1 and HMGA2) and GAPDH internal control were shown in
8,9) Additional positive markers include CD9, CD11c, CD29, CD33, CD43, CD44, CD45, CD49d, CD49e, CD51, CD54
, CD71, and the high-affinity immunoglobulin E receptor.
In this study, fucoidan increased the viability of DCs, the production of interleukin-12 and tumor necrosis factor-alpha, and the expression of major histocompatibility complex class I, class II, CD54
, and CD86 molecules.
Visfatinin T hucre aktivasyonunda rol oynayan CD54
(ICAM1), CD40 ve CD80 gibi kostimulator molekullerin monositlerde hucre yuzey ekspresyonunu artirdigi gosterilmistir.
The IL-6 has been reported to activate myocyte cell surface marker of CD54
, and to facilitate adhesion and oxidative radical-mediated injury by activated lymphocyte in the myocardium (21).
Different from the cells stimulated by MRSA, no change was observed in the expressions of CD54
1) reported that sensitizers increase the expression of HLA-DR, CD54
, and CD86 on monocyte-derived DCs (Mo-DCs).
Abstract #114: A Randomized Phase II, Open-Label Study of Sipuleucel-T with Concurrent or Sequential Abiraterone Acetate (AA) in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): A Phase II study evaluating concurrent or sequential therapy with AA plus prednisone (P) in men with metastatic castrate resistant prostate cancer demonstrated no significant differences in median cumulative CD54
Monoclonal antibodies against CD14 and CD54
were obtained from AbD Serotec (Kidlington, UK) and monoclonal antibody against TLR4 from eBioscience (San Diego, CA, USA).